TOP TEN perturbations for 39496_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39496_s_at
Selected probe(set): 206864_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39496_s_at (206864_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-4.6993523
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-4.6061716
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondrosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-4.412545
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

immune cell study 6 (PB; naive) / immune cell study 6 (PB; CD21lo)

Relative Expression (log2-ratio):-4.264282
Number of Samples:2 / 2
Experimental immune cell study 6 (PB; naive)
Naive B-cells (CD20+/CD10-/CD27-) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27-.
Control immune cell study 6 (PB; CD21lo)
Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21lo) isolated from peripheral blood (PB) B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21lo.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):3.9878511
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):3.8409424
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

immune cell study 6 (PB; memory) / immune cell study 6 (PB; CD21lo)

Relative Expression (log2-ratio):-3.469307
Number of Samples:2 / 2
Experimental immune cell study 6 (PB; memory)
Memory B-cells (CD20+/CD10-/CD27+) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27+.
Control immune cell study 6 (PB; CD21lo)
Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21lo) isolated from peripheral blood (PB) B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21lo.

immune cell study 6 (PB; naive) / immune cell study 6 (PB; CD21hi)

Relative Expression (log2-ratio):-3.3192654
Number of Samples:2 / 2
Experimental immune cell study 6 (PB; naive)
Naive B-cells (CD20+/CD10-/CD27-) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27-.
Control immune cell study 6 (PB; CD21hi)
Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21hi) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21hi.

precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):3.286067
Number of Samples:15 / 5
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

diazinon study 1 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):2.9093113
Number of Samples:3 / 19
Experimental diazinon study 1 (48h)
HepG2 cells exposed to 250μM diazinon in DMSO solvent for 48 hours. ATCvet code:
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.